Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Intercept Pharmaceuticals Stock Quote

Intercept Pharmaceuticals (NASDAQ: ICPT)

Some price data may be temporarily unavailable.

Intercept Pharmaceuticals Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
ICPT +24.02% -83.30% -30.09% -2%
S&P +21.39% +84.94% +13.07% +288%

Intercept Pharmaceuticals Company Info

Intercept Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline includes OCALIVA, which is used for the treatment of biliary cholangitis, nonalcoholic steatohepatitis, sclerosing cholangitis and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in Morristown, NJ.

News & Analysis

The Fool has written over 200 articles on Intercept Pharmaceuticals.


Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.